These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 17965442

  • 1. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation.
    Vergunst CE, Gerlag DM, Dinant H, Schulz L, Vinkenoog M, Smeets TJ, Sanders ME, Reedquist KA, Tak PP.
    Rheumatology (Oxford); 2007 Dec; 46(12):1773-8. PubMed ID: 17965442
    [Abstract] [Full Text] [Related]

  • 2. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis.
    Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, Morgan S, Nash AF, Tak PP.
    Arthritis Rheum; 2004 Dec; 50(12):3783-91. PubMed ID: 15593225
    [Abstract] [Full Text] [Related]

  • 3. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial.
    Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, van den Bosch F, Dinant HJ, Lee Y, Wyant T, Jacobson EW, Baeten D, Tak PP.
    Arthritis Rheum; 2008 Jul; 58(7):1931-9. PubMed ID: 18576354
    [Abstract] [Full Text] [Related]

  • 4. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study.
    Boumans MJ, Houbiers JG, Verschueren P, Ishikura H, Westhovens R, Brouwer E, Rojkovich B, Kelly S, den Adel M, Isaacs J, Jacobs H, Gomez-Reino J, Holtkamp GM, Hastings A, Gerlag DM, Tak PP.
    Ann Rheum Dis; 2012 Feb; 71(2):180-5. PubMed ID: 21917822
    [Abstract] [Full Text] [Related]

  • 5. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.
    Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, Loetscher P, Schmouder R, Woodworth T, Tak PP.
    Arthritis Rheum; 2006 Aug; 54(8):2387-92. PubMed ID: 16869001
    [Abstract] [Full Text] [Related]

  • 6. Expression of C5aR (CD88) of synoviocytes isolated from patients with rheumatoid arthritis and osteoarthritis.
    Yuan G, Wei J, Zhou J, Hu H, Tang Z, Zhang G.
    Chin Med J (Engl); 2003 Sep; 116(9):1408-12. PubMed ID: 14527377
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M.
    Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
    [Abstract] [Full Text] [Related]

  • 8. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP.
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [Abstract] [Full Text] [Related]

  • 9. Effects of clarithromycin in patients with active rheumatoid arthritis.
    Ogrendik M.
    Curr Med Res Opin; 2007 Mar; 23(3):515-22. PubMed ID: 17355733
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats.
    Iyer A, Woodruff TM, Wu MC, Stylianou C, Reid RC, Fairlie DP, Taylor SM, Brown L.
    J Cardiovasc Pharmacol; 2011 Nov; 58(5):479-86. PubMed ID: 21753735
    [Abstract] [Full Text] [Related]

  • 11. Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks.
    Lisbona MP, Maymo J, Perich J, Almirall M, Pérez-García C, Carbonell J.
    J Rheumatol; 2008 Mar; 35(3):394-7. PubMed ID: 18203329
    [Abstract] [Full Text] [Related]

  • 12. Dynamic T cell receptor clonotype changes in synovial tissue of patients with early rheumatoid arthritis: effects of treatment with cyclosporin A (Neoral).
    VanderBorght A, De Keyser F, Geusens P, De Backer M, Malaise M, Baeten D, Van den Bosch F, Veys EM, Raus J, Stinissen P.
    J Rheumatol; 2002 Mar; 29(3):416-26. PubMed ID: 11908552
    [Abstract] [Full Text] [Related]

  • 13. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.
    Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, Rosner I, Rozenbaum M, Mader R, Adawi M, Caspi D, Tishler M, Langevitz P, Rubinow A, Friedman J, Green L, Tanay A, Ochaion A, Cohen S, Kerns WD, Cohn I, Fishman-Furman S, Farbstein M, Yehuda SB, Fishman P.
    J Rheumatol; 2008 Jan; 35(1):41-8. PubMed ID: 18050382
    [Abstract] [Full Text] [Related]

  • 14. Effects of high dose IV pamidronate on disease activity and bone metabolism in patients with active RA: a randomized, double-blind, placebo-controlled trial.
    Lodder MC, Van Pelt PA, Lems WF, Kostense PJ, Koks CH, Dijkmans BA.
    J Rheumatol; 2003 Sep; 30(9):2080-1. PubMed ID: 12966622
    [No Abstract] [Full Text] [Related]

  • 15. Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis.
    Klimiuk PA, Sierakowski S, Latosiewicz R, Skowronski J, Cylwik JP, Cylwik B, Chwiecko J.
    J Rheumatol; 2005 Sep; 32(9):1666-72. PubMed ID: 16142858
    [Abstract] [Full Text] [Related]

  • 16. Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats.
    Arumugam TV, Woodruff TM, Stocks SZ, Proctor LM, Pollitt S, Shiels IA, Reid RC, Fairlie DP, Taylor SM.
    J Hepatol; 2004 Jun; 40(6):934-41. PubMed ID: 15158333
    [Abstract] [Full Text] [Related]

  • 17. The effect of ingestion of ferrous sulfate on the absorption of oral methotrexate in patients with rheumatoid arthritis.
    Hamilton SF, Campbell NR, Kara M, Watson J, Connors M.
    J Rheumatol; 2003 Sep; 30(9):1948-50. PubMed ID: 12966595
    [Abstract] [Full Text] [Related]

  • 18. C5a and C5aR are elevated in joints of rheumatoid and psoriatic arthritis patients, and C5aR blockade attenuates leukocyte migration to synovial fluid.
    Hornum L, Hansen AJ, Tornehave D, Fjording MS, Colmenero P, Wätjen IF, Søe Nielsen NH, Bliddal H, Bartels EM.
    PLoS One; 2017 Sep; 12(12):e0189017. PubMed ID: 29220376
    [Abstract] [Full Text] [Related]

  • 19. Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo.
    Smeets TJ, Kraan MC, Versendaal J, Breedveld FC, Tak PP.
    J Rheumatol; 1999 Oct; 26(10):2089-93. PubMed ID: 10529122
    [Abstract] [Full Text] [Related]

  • 20. Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model.
    Atkinson SM, Nansen A, Usher PA, Sondergaard BC, Mackay CR, Friedrichsen B, Chang CC, Tang R, Skov S, Haase C, Hornum L.
    Autoimmunity; 2015 Oct; 48(7):460-70. PubMed ID: 25915570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.